Therapeutic potential of kakkatin derivatives against hepatocellular carcinoma

doi:10.5306/wjco.v16.i3.101686

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (327)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

181

Figures (1-1)

Sum=273

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=38

Mar 24, 2025 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Mar 24, 2025; 16(3): 101686
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.101686

Therapeutic potential of kakkatin derivatives against hepatocellular carcinoma

Sahiba Chahal, Vikram Patial

Sahiba Chahal, Vikram Patial, Dietetics and Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur 176061, Himachal Pradesh, India

Sahiba Chahal, Vikram Patial, Academy of Scientific and Innovative Research Headquarters, Ghaziabad 201002, Uttar Pradesh, India

Author contributions: Chahal S collected the literature and wrote the manuscript; Patial V contributed to designing, manuscript writing, and editing; All authors have read and approved the final manuscript.

Supported by the Indian Council of Scientific and Industrial Research, No. MLP0204 (CSIR-IHBT no. 5712).

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Vikram Patial, Principal Scientist, PhD, Dietetics and Nutrition Technology Division, CSIR-Institute of Himalayan Bioresource Technology, No. 6 Post Box, Palampur 176061, Himachal Pradesh, India. vikrampatial@ihbt.res.in

Received: September 23, 2024
Revised: November 12, 2024
Accepted: December 2, 2024
Published online: March 24, 2025
Processing time: 120 Days and 0.3 Hours

Core Tip

Core Tip: The heterogeneity of tumor cells and their ability to migrate, invade, and metastasize distant tissue makes diagnosing and developing a cancer treatment difficult. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths, and current therapies are either only effective at the early stage or have side effects. Puerariae flos-based treatment of HCC has shown a better potential to treat HCC than the known chemotherapeutic drug cisplatin. Kakkatin and its derivative 6-(hept-6-yn-1-yloxy)-3-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one, derived from puerariae flos, were used as treatment against HCC and compared with cisplatin.